Therapeutic Armamentarium for Treating Depression

References

• . Hirschfeld RM, Weissman MM. Risk factors for major depression and bipolar disorder. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002:1017–1025
   Google Scholar
• . Kessler RC, McGonagle KA, Zhao S,. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19
   PubMed Web of Science ®Google Scholar
• . Kessler RC, Berglund P, Demler O,; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105
   PubMed Web of Science ®Google Scholar
• . Steiner M, Bell B, Browne G,. Prevalence of dysthymic disorder in primary care. J Affect Disord. 1999;54(3):303–308
   PubMed Web of Science ®Google Scholar
• . Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord. 1997;45(1–2):19–30
   PubMed Web of Science ®Google Scholar
• . Howland RH. General health, health care utilization, and medical comorbidity in dysthymia. Int J Psychiatry Med. 1993;23(3):211–238
   PubMed Web of Science ®Google Scholar
• . Howland RH, Schettler PJ, Rapaport MH,. Clinical features and functioning of patients with minor depression. Psychother Psychosom. 2008;77(6):384–389
   PubMed Web of Science ®Google Scholar
• . Rush AJ, Kraemer HC, Sackeim HA,; ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841–1853
   PubMed Web of Science ®Google Scholar
• . Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–659
   PubMed Web of Science ®Google Scholar
• . Howland RH, Thase ME. Switching strategies for the treatment of unipolar major depression. In: Rush AJ, ed. Mood Disorders: Systematic Medication Management (Modern Problems of Pharmacopsychiatry). Vol 25. Basel, Switzerland: S. Karger AG Publishers; 1997:56–65
   Google Scholar
• . Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry. 1998;59( suppl 5):5–12
   PubMed Web of Science ®Google Scholar
• . Trivedi MH, Hollander E, Nutt D, Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 2008;69(2):246–258
   PubMed Web of Science ®Google Scholar
• . Carney RM, Freedland KE. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry. 2009;166(4):410–417
   PubMed Web of Science ®Google Scholar
• . Crown WH, Finkelstein S, Berndt ER,. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963–971
   PubMed Web of Science ®Google Scholar
• . Dunner DL, Rush AJ, Russell JM,. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67(5):688–695
   PubMed Web of Science ®Google Scholar
• . Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116(1–2):4–11
   PubMed Web of Science ®Google Scholar
• . Russell JM, Hawkins K, Ozminkowski RJ,. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341–347
   PubMed Web of Science ®Google Scholar
• . Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine. 2006;3(11):e442
   PubMed Web of Science ®Google Scholar
• . González HM, Vega WA, Williams DR, Tarraf W, West BT, Neighbors HW. Depression care in the United States: too little for too few. Arch Gen Psychiatry. 2010;67(1):37–46
   PubMed Web of Science ®Google Scholar
• . Kocsis JH, Gelenberg AJ, Rothbaum B,. Chronic forms of depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. J Affect Disord. 2008;110(1–2):55–61
   PubMed Web of Science ®Google Scholar
• . Sartorius N, Baghai TC, Baldwin DS,. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol. 2007;10( suppl 1):S1–S207
   Web of Science ®Google Scholar
• . Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185–219
   PubMed Web of Science ®Google Scholar
• . Howland RH. MAOI antidepressant drugs. J Psychosoc Nurs Ment Health Serv. 2006;44(6):9–12
   Web of Science ®Google Scholar
• . Howland RH. Transdermal selegiline: a novel MAOI formulation for depression. J Psychosoc Nurs Ment Health Serv. 2006;44(7):9–12
   Web of Science ®Google Scholar
• . Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62(11):1217–1227
   PubMed Web of Science ®Google Scholar
• . Nakagawa A, Watanabe N, Omori IM,; Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: a systematic review and meta-analysis. CNS Drugs. 2008;22(7):587–602
   PubMed Web of Science ®Google Scholar
• . Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord. 1997;21( suppl 1):S25–S29
   Web of Science ®Google Scholar
• . Markowitz JS, Patrick KS. Venlafaxine-tramadol similarities. Med Hypotheses. 1998;51(2):167–168
   PubMed Web of Science ®Google Scholar
• . Reeves RR, Cox SK. Similar effects of tramadol and venlafaxine in major depressive disorder. South Med J. 2008;101(2):193–195
   PubMed Web of Science ®Google Scholar
• . Howland RH. Understanding the clinical profile of a drug on the basis of its pharmacology: mirtazapine as an example. J Psychosoc Nurs Ment Health Serv. 2008;46(12):19–23
   Web of Science ®Google Scholar
• . Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67(12):1836–1855
   PubMed Web of Science ®Google Scholar
• . Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63(7):699–704
   PubMed Web of Science ®Google Scholar
• . Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression—a retrospective study. J Affect Disord. 2005;89(1–3):183–188
   PubMed Web of Science ®Google Scholar
• . Thase ME, Rush AJ, Howland RH,. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59(3):233–239
   PubMed Web of Science ®Google Scholar
• . Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75(3):139–153
   PubMed Web of Science ®Google Scholar
• . de la Gándara J, Rojo JE, Ros S, Agüera L, de Pedro JM. Neuropharmacological basis of combining antidepressants. Acta Psychiatr Scand Suppl. 2005;428:11–13, 36
   Google Scholar
• . Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry. 2002;63(8):685–693
   PubMed Web of Science ®Google Scholar
• . Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006;59(3):203–210
   PubMed Web of Science ®Google Scholar
• . Rush AJ, Trivedi MH, Wisniewski SR,. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917
   PubMed Web of Science ®Google Scholar
• . Trivedi MH, Rush AJ, Wisniewski SR,. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40
   PubMed Web of Science ®Google Scholar
• . Trivedi MH, Fava M, Wisniewski SR,; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243–1252
   PubMed Web of Science ®Google Scholar
• . Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183–188
   PubMed Web of Science ®Google Scholar
• . McGrath PJ, Stewart JW, Fava M,. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531–1541
   PubMed Web of Science ®Google Scholar
• . Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55(3):296–300
   PubMed Web of Science ®Google Scholar
• . Blier P, Gobbi G, Turcotte JE,. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initation. Eur Neuropsychopharmacol. 2009;19(7):457–465
   PubMed Web of Science ®Google Scholar
• . Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281–288
   PubMed Web of Science ®Google Scholar
• . Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68(6):935–940
   PubMed Web of Science ®Google Scholar
• . Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry. 2006;163(7):1219–1225
   PubMed Web of Science ®Google Scholar
• . Nierenberg AA, Fava M, Trivedi MH,. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519–1530
   PubMed Web of Science ®Google Scholar
• . Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol. 2003;23(2):182–192
   PubMed Web of Science ®Google Scholar
• . Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002;63(8):737–741
   PubMed Web of Science ®Google Scholar
• . Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress Anxiety. 2006;23(8):485–488
   PubMed Web of Science ®Google Scholar
• . Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003;64(4):403–407
   PubMed Web of Science ®Google Scholar
• . Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol. 2007;22(3):179–182
   PubMed Web of Science ®Google Scholar
• . Zhang ZJ, Tan QR, Tong Y,. The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study. J Affect Disord. 2008;109(1–2):91–97
   PubMed Web of Science ®Google Scholar
• . Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology. 1999;40(3):134–139
   PubMed Web of Science ®Google Scholar
• . Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117(4):253–259
   PubMed Web of Science ®Google Scholar
• . Berman RM, Fava M, Thase ME,. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197–206
   PubMed Web of Science ®Google Scholar
• . Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540–549
   PubMed Web of Science ®Google Scholar
• . Daly EJ, Trivedi MH. A review of quetiapine in combination with antidepressant therapy in patients with depression. Neuropsychiatr Dis Treat. 2007;3(6):855–867
   PubMedGoogle Scholar
• . Trivedi MH, Thase ME, Osuntokun O,. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry. 2009;70(3):387–396
   PubMed Web of Science ®Google Scholar
• . Mahmoud RA, Pandina GJ, Turkoz I,. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593–602
   PubMed Web of Science ®Google Scholar
• . Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry. 2007;68(7):1071–1077
   PubMed Web of Science ®Google Scholar
• . Rosa AR, Franco C, Torrent C,. Ziprasidone in the treatment of affective disorders: a review. CNS Neurosci Ther. 2008; 14(4):278–286
   PubMed Web of Science ®Google Scholar
• . Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol. 2010;24(4):513–520
   PubMed Web of Science ®Google Scholar
• . Landén M, Björling G, Agren H, Fahlén T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59(12):664–668
   PubMed Web of Science ®Google Scholar
• . Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62(6):448–452
   PubMed Web of Science ®Google Scholar
• . Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry. 1989;50(7):241–249
   PubMed Web of Science ®Google Scholar
• . Hardy SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother. 2009;7(1):34–59
   PubMed Web of Science ®Google Scholar
• . Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991;11(2):127–132
   PubMed Web of Science ®Google Scholar
• . Patkar AA, Masand PS, Pae CU,. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653–656
   PubMed Web of Science ®Google Scholar
• . Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008;69(1):87–94
   PubMed Web of Science ®Google Scholar
• . Pae CU, Marks DM, Masand PS,. Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32(2):85–88
   PubMed Web of Science ®Google Scholar
• . Michelson D, Adler LA, Amsterdam JD,. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(4):582–587
   PubMed Web of Science ®Google Scholar
• . Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res. 2006;40(4):370–373
   PubMed Web of Science ®Google Scholar
• . Fava M, Thase ME, DeBattista C, Doghramji K Arora S, Hughes RJ. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19(3):153–158
   PubMedGoogle Scholar
• . Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. 2009;61(2):105–123
   PubMed Web of Science ®Google Scholar
• . Mitchell ND, Baker GB. An update on the role of glutamate in the pathophysiology of depression [published online ahead of print January 25, 2010]. Acta Psychiatr Scand.
   Google Scholar
• . Wolff K, Winstock AR. Ketamine: from medicine to misuse. CNS Drugs. 2006;20(3):199–218
   PubMed Web of Science ®Google Scholar
• . Zarate CA Jr, Singh JB, Carlson PJ,. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864
   PubMed Web of Science ®Google Scholar
• . Anand A, Charney DS, Oren DA,. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270–276
   PubMed Web of Science ®Google Scholar
• . Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82
   PubMed Web of Science ®Google Scholar
• . Bryson HM, Fulton B, Benfield P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs. 1996;52(4):549–563
   PubMed Web of Science ®Google Scholar
• . Sanacora G, Kendell SF, Levin Y,. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007;61(6):822–825
   PubMed Web of Science ®Google Scholar
• . Zarate CA Jr, Payne JL, Quiroz J,. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161(1):171–174
   PubMed Web of Science ®Google Scholar
• . Zarate CA Jr, Quiroz JA, Singh JB,. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430–432
   PubMed Web of Science ®Google Scholar
• . Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer's disease. Drugs. 2006;66(11):1515–1534
   PubMed Web of Science ®Google Scholar
• . Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6(1):61–67
   PubMed Web of Science ®Google Scholar
• . Zarate CA Jr, Singh JB, Quiroz JA,. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153–155
   PubMed Web of Science ®Google Scholar
• . Olsen RW. GABA. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002:159–168
   Google Scholar
• . Krystal JH, Sanacora G, Blumberg H,. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7( suppl 1):S71–S80
   PubMed Web of Science ®Google Scholar
• . Becker PM, Sattar M. Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol. 2009;11(5):349–357
   PubMed Web of Science ®Google Scholar
• . Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs. 2007;21(12):995–1018
   PubMed Web of Science ®Google Scholar
• . Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci. 2000;25(1):48–52
   PubMed Web of Science ®Google Scholar
• . Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry. 1998;155(8):1119–1121
   PubMed Web of Science ®Google Scholar
• . Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat. 2009;5:563–576
   PubMed Web of Science ®Google Scholar
• . Rajaratnam SW, Cohen DA, Rogers NL. Melatonin and melatonin analogs. Sleep Med Clin. 2009;4:179–193
   Google Scholar
• . Manber R, Chambers AS. Insomnia and depression: a multifaceted interplay. Curr Psychiatry Rep. 2009;11(6):437–442
   PubMed Web of Science ®Google Scholar
• . Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev. 2004;8(1):19–30
   PubMed Web of Science ®Google Scholar
• . Fava M, McCall WV, Krystal A,. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052–1060
   PubMed Web of Science ®Google Scholar
• . Morishita S. Clonazepam as a therapeutic adjunct to improve the management of depression: a brief review. Hum Psychopharmacol. 2009;24(3):191–198
   PubMed Web of Science ®Google Scholar
• . Warner MD, Peabody CA, Whiteford HA, Hollister LE. Alprazolam as an antidepressant. J Clin Psychiatry. 1988;49(4):148–150
   PubMed Web of Science ®Google Scholar
• . Picciotto MR, Alreja M, Jentsch JD. Acetylcholine. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002:3–14
   Google Scholar
• . McCarley RW. REM sleep and depression: common neurobiological control mechanisms. Am J Psychiatry. 1982;139(5):565–570
   PubMed Web of Science ®Google Scholar
• . Kasper S, Moises HW, Beckmann H. The anticholinergic biperiden in depressive disorders. Pharmacopsychiatria. 1981;14(6):195–198
   PubMedGoogle Scholar
• . Beckmann H, Moises HW. The cholinolytic biperiden in depression. An acute placebo controlled study. Arch Psychiatr Nervenkr. 1982;231(3):213–220
   PubMedGoogle Scholar
• . Gillin JC, Lauriello J, Kelsoe JR,. No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. Psychiatry Res. 1995;58(2):99–105
   PubMed Web of Science ®Google Scholar
• . Goldner RD. Scopolamine sleep treatment in private practise. Int J Neuropsychiatry. 1967;3(3):234–247
   PubMedGoogle Scholar
• . Newhouse PA, Sunderland T, Tariot PN,. The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry. 1988;45(10):906–912
   PubMed Web of Science ®Google Scholar
• . Gillin JC, Sutton L, Ruiz C,. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry. 1991;30(2):157–169
   PubMed Web of Science ®Google Scholar
• . Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121–1129
   PubMed Web of Science ®Google Scholar
• . Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67(5):432–438
   PubMed Web of Science ®Google Scholar
• . Lippiello PM, Beaver JS, Gatto GJ,. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther. 2008;14(4):266–277
   PubMed Web of Science ®Google Scholar
• . Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther. 2009;31(3):463–491
   PubMed Web of Science ®Google Scholar
• . McNally GP, Akil H. Opioid peptides and their receptors: overview and function in pain modulation. In: Davis KL, Charney D, Coyle JT, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002:35–46
   Google Scholar
• . Berrocoso E, Sánchez-Blázquez P, Garzón J, Mico JA. Opiates as antidepressants. Curr Pharm Des. 2009;15(14):1612–1622
   PubMed Web of Science ®Google Scholar
• . Gold MS, Pottash AC, Sweeney D, Martin D, Extein I. Antimanic, antidepressant, and antipanic effects of opiates: clinical, neuroanatomical, and biochemical evidence. Ann N Y Acad Sci. 1982;398:140–150
   PubMed Web of Science ®Google Scholar
• . Fink M, Simeon J, Itil TM, Freedman AM. Clinical antidepressant activity of cyclazocine—a narcotic antagonist. Clin Pharmacol Ther. 1970;11(1):41–48
   PubMed Web of Science ®Google Scholar
• . Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7(1):51–54
   PubMed Web of Science ®Google Scholar
• . Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57
   PubMed Web of Science ®Google Scholar
• . Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008;28(5):593–595
   PubMed Web of Science ®Google Scholar
• . Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci. 1982;398:108–112
   PubMed Web of Science ®Google Scholar
• . Chuong CJ, Coulam CB, Bergstralh EJ, O'Fallon WM, Steinmetz GI. Clinical trial of naltrexone in premenstrual syndrome. Obstet Gynecol. 1988;72(3 pt 1):332–336
   PubMed Web of Science ®Google Scholar
• . Stryjer R, Strous RD, Shaked G,. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol. 2003;18(2):93–96
   PubMed Web of Science ®Google Scholar
• . Rogóz Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep. 2007;59(6):778–784
   PubMed Web of Science ®Google Scholar
• . Inoue T, Tsuchiya K, Miura J,. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry. 1996;40(2):151–153
   PubMed Web of Science ®Google Scholar
• . Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11(2):58–65
   PubMed Web of Science ®Google Scholar
• . Cassano P, Lattanzi L, Soldani F,. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety. 2004;20(3):131–138
   PubMed Web of Science ®Google Scholar
• . Cassano P, Lattanzi L, Fava M,. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry. 2005;50(6):357–360
   PubMed Web of Science ®Google Scholar
• . Sharpley CF. Neurobiological pathways between chronic stress and depression: dysregulated adaptive mechanisms? Clin Med Psychiatry. 2009;2:33–45
   Google Scholar
• . de Souza EB, Grigoriadis DE. Corticotropin-releasing factor: physiology, pharmacology, and role in central nervous system disorders. In: Davis KL, Charney D, Coyle JT, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002:91–107
   Google Scholar
• . Reus VI, Wolkowitz OM. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs. 2001;10(10):1789–1796
   PubMed Web of Science ®Google Scholar
• . Dinan TG, Lavelle E, Cooney J,. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand. 1997;95(1):58–61
   PubMed Web of Science ®Google Scholar
• . Malison RT, Anand A, Pelton GH,. Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol. 1999;19(5):466–470
   PubMed Web of Science ®Google Scholar
• . Murphy BE, Ghadirian AM, Dhar V. Neuroendocrine responses to inhibitors of steroid biosynthesis in patient with major depression resistant to antidepressant therapy. Can J Psychiatry. 1998;43(3):279–286
   PubMed Web of Science ®Google Scholar
• . Rogóz Z, Skuza G, Wójcikowski J,. Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Pol J Pharmacol. 2004;56(6):849–855
   PubMedGoogle Scholar
• . Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med. 1999;61(5):698–711
   PubMed Web of Science ®Google Scholar
• . Wolkowitz OM, Reus VI, Chan T,. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry. 1999;45(8):1070–1074
   PubMed Web of Science ®Google Scholar
• . Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61(12):1235–1244
   PubMed Web of Science ®Google Scholar
• . Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol. 2008;20(10):1101–1114
   PubMed Web of Science ®Google Scholar
• . Howland RH. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. J Clin Psychiatry. 1993;54(2):47–54
   PubMed Web of Science ®Google Scholar
• . Abraham G, Milev R, Stuart Lawson J. T3 augmentation of SSRI resistant depression. J Affect Disord. 2006;91(2–3):211–215
   PubMed Web of Science ®Google Scholar
• . Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50(5):387–393
   PubMed Web of Science ®Google Scholar
• . Whybrow PC. Sex differences in thyroid axis function: relevance to affective disorder and its treatment. Depression. 1995;3:33–42
   Google Scholar
• . Papakostas GI, Cooper-Kazaz R, Appelhof BC,. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol. 2009;24(1):19–25
   PubMed Web of Science ®Google Scholar
• . Payne JL, Palmer JT, Joffe H. A reproductive subtype of depression: conceptualizing models and moving toward etiology. Harv Rev Psychiatry. 2009;17(2):72–86
   PubMed Web of Science ®Google Scholar
• . Margolese HC. The male menopause and mood: testosterone decline and depression in the aging male—is there a link? J Geriatr Psychiatry Neurol. 2000;13(2):93–101
   PubMed Web of Science ®Google Scholar
• . Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry. 2009;70(7):1009–1016
   PubMed Web of Science ®Google Scholar
• . Deecher D, Andree TH, Sloan D, Schechter LE. From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology. 2008;33(1):3–17
   PubMed Web of Science ®Google Scholar
• . Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry. 1998;44(9):798–811
   PubMed Web of Science ®Google Scholar
• . Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61(5):676–697
   PubMed Web of Science ®Google Scholar
• . Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry. 2005;66(6):774–780
   PubMed Web of Science ®Google Scholar
• . Morrison MF, Kallan MJ, Ten Have T, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55(4):406–412
   PubMed Web of Science ®Google Scholar
• . Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58(6):529–534
   PubMed Web of Science ®Google Scholar
• . Amsterdam J, Garcia-España F, Fawcett J,. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55(1):11–17
   PubMed Web of Science ®Google Scholar
• . Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry. 1997;5(2):97–106
   PubMed Web of Science ®Google Scholar
• . Shapira B, Oppenheim G, Zohar J, Segal M, Malach D, Belmaker RH. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry. 1985;20(5):576–579
   PubMed Web of Science ®Google Scholar
• . Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18(1):20–24
   PubMed Web of Science ®Google Scholar
• . Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry. 2001;62(6):406–412
   PubMed Web of Science ®Google Scholar
• . Kanayama G, Amiaz R, Seidman S, Pope HG Jr. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp Clin Psychopharmacol. 2007;15(6):529–538
   PubMed Web of Science ®Google Scholar
• . Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry. 1999;45(12):1533–1541
   PubMed Web of Science ®Google Scholar
• . Schmidt PJ, Daly RC, Bloch M,. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005;62(2):154–162
   PubMed Web of Science ®Google Scholar
• . Wolkowitz OM, Reus VI, Keebler A,. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999;156(4):646–649
   PubMed Web of Science ®Google Scholar
• . Wells RA, Giannetti VJ, eds. Handbook of the Brief Psychotherapies. New York, NY: Plenum Press; 1990
   Google Scholar
• . Frank E, Novick D, Kupfer DJ. Antidepressants and psychotherapy: a clinical research review. Dialogues Clin Neurosci. 2005;7(3):263–272
   PubMedGoogle Scholar
• . Persons JB, Thase ME, Crits-Christoph P. The role of psychotherapy in the treatment of depression: review of two practice guidelines. Arch Gen Psychiatry. 1996;53(4):283–290
   PubMed Web of Science ®Google Scholar
• . Rush AJ, Thase ME. Psychotherapies for depressive disorders: a review. In: Maj M, Sartorius N, eds. WPA Series: Evidence and Experience in Psychiatry. Vol 1. Depressive Disorders. Chichester, England: John Wiley & Sons, Ltd; 1999:161–206
   Google Scholar
• . Gilbert P, Gilbert J, Irons C. Life events, entrapments and arrested anger in depression. J Affect Disord. 2004;79(1–3):149–160
   PubMed Web of Science ®Google Scholar
• . Ogrodniczuk JS, Piper WE, Joyce AS. Alexithymia as a predictor of residual symptoms in depressed patients who respond to short-term psychotherapy. Am J Psychother. 2004;58(2):150–161
   PubMedGoogle Scholar
• . Leichsenring F, Rabung S, Leibing E. The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry. 2004;61(12):1208–1216
   PubMed Web of Science ®Google Scholar
• . Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004;61(7):714–719
   PubMed Web of Science ®Google Scholar
• . Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES. Interpersonal Psychotherapy of Depression. New York, NY: Basic Books; 1984
   Google Scholar
• . Klerman GL, Weissman MM. New Applications of Interpersonal Psychotherapy. Washington, DC: American Psychiatric Press; 1993
   Google Scholar
• . Markowitz JC. Interpersonal Psychotherapy for Dysthymic Disorder. Washington, DC: American Psychiatric Press; 1998
   Google Scholar
• . Weissman MM, Markowitz JC. Interpersonal psychotherapy. Current status. Arch Gen Psychiatry. 1994;51(8):599–606
   PubMed Web of Science ®Google Scholar
• . Becker RE, Heimberg RG, Bellack AS. Social Skills Training Treatment for Depression. New York, NY: Pergamon Press; 1987
   Google Scholar
• . Hersen M, Himmelhoch JM, Thase ME, Bellack AS. Effects of social skill training, amitriptyline, and psychotherapy in unipolar depressed women. Behav Ther. 1984;15(1):21–40
   Web of Science ®Google Scholar
• . Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy for Depression. New York, NY: Guilford Press; 1979
   Google Scholar
• . Clark DM, Fairburn CG, eds. Science and Practice of Cognitive Behaviour Therapy. New York, NY: Oxford University Press; 1997
   Google Scholar
• . Hollon SD, DeRubeis RJ, Evans MD,. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Arch Gen Psychiatry. 1992;49(10):774–781
   PubMed Web of Science ®Google Scholar
• . McCullough JP Jr. Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy. New York, NY: Guilford Press; 2000
   Google Scholar
• . Keller MB, McCullough JP, Klein DN,. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462–1470
   PubMed Web of Science ®Google Scholar
• . Schatzberg AF, Rush AJ, Arnow BA,. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry, 2005;62(5):513–520
   PubMed Web of Science ®Google Scholar
• . Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009;70(9):1219–1229
   PubMed Web of Science ®Google Scholar
• . Howland RH, Thase ME. Combining psychotherapy and pharmacotherapy for depression and anxiety. In: Kasper S, den Boer JA, Ad Sitsen JM, eds. Handbook of Depression and Anxiety. 2nd ed. New York, NY: Marcel Dekker, Inc; 2003:151–163
   Google Scholar
• . Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psychiatry. 2001;62( suppl 18):18–24
   Web of Science ®Google Scholar
• . Abbass AA. Intensive short-term dynamic psychotherapy of treatment-resistant depression: a pilot study. Depress Anxiety. 2006;23(7):449–452
   PubMed Web of Science ®Google Scholar
• . Martin SD, Martin E, Hildreth A,. Preliminary IBZM-SPECT correlates of treatment resistant depression managed with interpersonal psychotherapy and mirtazapine [abstract 029]. J Neurol Neurosurg Psychiatry. 2007;78:785
   Google Scholar
• . Eisendrath SJ, Delucchi K, Bitner R, Fenimore P, Smit M, McLane M. Mindfulness-based cognitive therapy for treatment-resistant depression: a pilot study. Psychother Psychosom. 2008;77(5):319–320
   PubMed Web of Science ®Google Scholar
• . Wiles NJ, Hollinghurst S, Mason V,. A randomized controlled trial of cognitive behavioural therapy as an adjunct to pharmacotherapy in primary care based patients with treatment resistant depression: a pilot study. Behav Cog Psychother. 2008;36:21–33
   Web of Science ®Google Scholar
• . Bottonari KA, Roberts JE, Thomas SN, Read JP. Stop thinking and start doing: switching from cognitive therapy to behavioral activation in a case of chronic treatment-resistant depression. Cog Behav Prac. 2008;15:376–386
   Web of Science ®Google Scholar
• . Thase ME, Friedman ES, Biggs MM,. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739–752
   PubMed Web of Science ®Google Scholar
• . Trivedi MH, Kocsis JH, Thase ME,. REVAMP—Research Evaluating the Value of Augmenting Medication with Psychotherapy: Rationale and design. Psychopharmacol Bull. 2008;41(4):5–33
   PubMedGoogle Scholar
• . Kocsis JH, Gelenberg AJ, Rothbaum BO,; REVAMP Investigators. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry. 2009;66(11):1178–1188
   PubMed Web of Science ®Google Scholar
• . Teychenne M, Ball K, Salmon J. Physical activity and likelihood of depression in adults: a review. Prev Med. 2008;46(5):397–411
   PubMed Web of Science ®Google Scholar
• . Blake H, Mo P, Malik S, Thomas S. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clin Rehabil. 2009;23(10):873–887
   PubMed Web of Science ®Google Scholar
• . Daley A. Exercise and depression: a review of reviews. J Clin Psychol Med Settings. 2008;15(2):140–147
   PubMed Web of Science ®Google Scholar
• . Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ. 2001;322(7289):763–767
   PubMed Web of Science ®Google Scholar
• . Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. Cochrane Database Syst Rev. 2008;(4):CD004366
   Google Scholar
• . Stathopoulou G, Powers M, Berry A, Smits J, Otto M. Exercise interventions for mental health: a quantitative and qualitative review. Clin Psychol Sci Pract. 2006;13(2):179–193
   Web of Science ®Google Scholar
• . Otto MW, Church TS, Craft LL, Greer TL, Smits JA, Trivedi MH. Exercise for mood and anxiety disorders. Prim Care Companion J Clin Psychiatry. 2007;9(4):287–294
   PubMedGoogle Scholar
• . Perraton LG, Kumar S, Machotka Z. Exercise parameters in the treatment of clinical depression: a systematic review of randomized controlled trials [published online ahead of print December 18, 2009]. J Eval Clin Pract.
   Google Scholar
• . Trivedi MH, Greer TL, Grannemann BD,. TREAD: TReatment with Exercise Augmentation for Depression: study rationale and design. Clin Trials. 2006;3(3):291–305
   PubMed Web of Science ®Google Scholar
• . Pilu A, Sorba M, Hardoy MC,. Efficacy of physical activity in the adjunctive treatment of major depressive disorders: preliminary results. Clin Pract Epidemiol Ment Health. 2007;3:8
   PubMedGoogle Scholar
• . Trivedi MH, Greer TL, Grannemann BD, Chambliss HO, Jordan AN. Exercise as an augmentation strategy for treatment of major depression. J Psychiatr Pract. 2006;12(4):205–213
   PubMedGoogle Scholar
• . Barbour KA, Edenfield TM, Blumenthal JA. Exercise as a treatment for depression and other psychiatric disorders: a review. J Cardiopulm Rehabil Prev. 2007;27(6):359–367
   PubMed Web of Science ®Google Scholar
• . Ernst C, Olson AK, Pinel JP, Lam RW, Christie BR. Antidepressant effects of exercise: evidence for an adult-neurogenesis hypothesis? Rev Psychiatry Neurosci. 2006;31(2):84–92
   PubMed Web of Science ®Google Scholar
• . Lucassen PJ, Meerlo P, Naylor AS,. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action. Eur Neuropsychopharmacol. 2010;20(1):1–17
   PubMed Web of Science ®Google Scholar
• . Young SN. How to increase serotonin in the human brain without drugs. J Psychiatry Neurosci. 2007;32(6):394–399
   PubMed Web of Science ®Google Scholar
• . Howland RH. An overview of seasonal affective disorder and its treatment options. Phys Sportsmed. 2009;37(4):104–115
   PubMed Web of Science ®Google Scholar
• . Kripke DF. Light treatment for nonsensical major depression: are we ready? In: Lam RW, ed. Seasonal Affective Disorder and Beyond. Washington, DC: American Psychiatric Press; 1998:159–172
   Google Scholar
• . Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081–1097
   Google Scholar
• . Golden RN, Gaynes BN, Ekstrom RD,. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry. 2005;162(4):656–662
   PubMed Web of Science ®Google Scholar
• . Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal depression. Cochrane Database Syst Rev. 2004;(2):CD004050
   Google Scholar
• . Martiny K, Lunde M, Undén M, Dam H, Bech P. The lack of sustained effect of bright light, after discontinuation, in non-seasonal major depression. Psychol Med. 2006;36(9):1247–1252
   PubMed Web of Science ®Google Scholar
• . Wirz-Justice A. Biological rhythms in mood disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:999–1017
   Google Scholar
• . Giedke H, Schwärzler F. Therapeutic use of sleep deprivation in depression. Sleep Med Rev. 2002;6(5):361–377
   PubMed Web of Science ®Google Scholar
• . Benedetti F, Smeraldi E. Neuroimaging and genetics of antidepressant response to sleep deprivation: implications for drug development. Curr Pharm Des. 2009;15(22):2637–2649
   PubMed Web of Science ®Google Scholar
• . Colombo C, Lucca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. Psychiatry Res. 2000;95(1):43–53
   PubMed Web of Science ®Google Scholar
• . Fritzsche M, Heller R, Hill H, Kick H. Sleep deprivation as a predictor of response to light therapy in major depression. J Affect Disord. 2001;62(3):207–215
   PubMed Web of Science ®Google Scholar
• . Ulett GA, Han S, Han JS. Electroacupuncture: mechanisms and clinical application. Biol Psychiatry. 1998;44(2):129–138
   PubMed Web of Science ®Google Scholar
• . Allen JJB, Schnyer RN, Hitt SK. The efficacy of acupuncture in the treatment of major depression in women. Psychol Sci. 1998;4:397–401
   Google Scholar
• . Luo H, Meng F, Jia Y, Zhao X. Clinical research on the therapeutic effect of the electro-acupuncture treatment in patients with depression. Psychiatry Clin Neurosci. 1998;52( suppl):S338–S340
   Web of Science ®Google Scholar
• . Röschke J, Wolf C, Müller MJ,. The benefit from whole body acupuncture in major depression. J Affect Disord. 2000;57(1–3):73–81
   PubMed Web of Science ®Google Scholar
• . Zhang ZJ, Chen HY, Yip KC, Ng R, Wong VT. The effectiveness and safety of acupuncture therapy in depressive disorders: systematic review and meta-analysis. J Affect Disord. 2010;124(1–2):9–21
   PubMed Web of Science ®Google Scholar
• . Uebelacker LA, Epstein-Lubow G, Gaudiano BA, Tremont G, Battle CL, Miller IW. Hatha yoga for depression: critical review of the evidence for efficacy, plausible mechanisms of action, and directions for future research. J Psychiatr Pract. 2010;16(1):22–33
   PubMed Web of Science ®Google Scholar
• . Coelho HF, Boddy K, Ernst E. Massage therapy for the treatment of depression: a systematic review. Int J Clin Pract. 2008;62(2):325–333
   PubMed Web of Science ®Google Scholar
• . Hou WH, Chiang PT, Hsu TY, Chiu SY, Yen YC. Treatment effects of massage therapy in depressed people: a meta-analysis [published online ahead of print March 23, 2010]. J Clin Psychiatry.
   Google Scholar
• . Tsang HW, Chan EP, Cheung WM. Effects of mindful and non-mindful exercises on people with depression: a systematic review. Br J Clin Psychol. 2008;47(pt 3):303–322
   PubMed Web of Science ®Google Scholar
• . Tsang HW, Fung KM. A review on neurobiological and psychological mechanisms underlying the anti-depressive effect of qigong exercise. J Health Psychol. 2008;13(7):857–863
   PubMed Web of Science ®Google Scholar
• . Deplin product information. Deplin Web site. http://www.deplin.com/. Accessed May 25, 2010
   Google Scholar
• . Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr. 2007;12(10):739–744
   PubMed Web of Science ®Google Scholar
• . Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol. 2005;19(1):59–65
   PubMed Web of Science ®Google Scholar
• . Di Palma C, Urani R, Agricola R,. Is methylfolate effective in relieving major depression in chronic alcoholics? A hypothesis of treatment. Curr Ther Res Clin Exp. 1994;55:559–568
   Web of Science ®Google Scholar
• . Guaraldi GP, Fava M, Mazzi F, la Greca P. An open trial of methyltetrahy drofolate in elderly depressed patients. Ann Clin Psychiatry. 1993;5(2):101–105
   PubMedGoogle Scholar
• . Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002;14(1):33–38
   PubMedGoogle Scholar
• . Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol. 2004;18(2):251–256
   PubMed Web of Science ®Google Scholar
• . The Medical Letter on Drugs and Therapeutics. L-methylfolate (Deplin) for depression and schizophrenia. NeLM. 2010;52(1336):31–32
   Google Scholar
• . Godfrey PS, Toone BK, Carney MW,. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392–395
   PubMed Web of Science ®Google Scholar
• . Passeri M, Cucinotta D, Abate G,. Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano). 1993;5(1):63–71
   PubMedGoogle Scholar
• . Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60(2):121–130
   PubMed Web of Science ®Google Scholar
• . Resler G, Lavie R, Campos J,. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008;15(3):145–152
   PubMed Web of Science ®Google Scholar
• . Reynolds EH, Stramentinoli G. Folic acid, S-adenosylmethionine and affective disorder. Psychol Med. 1983;13(4):705–710
   PubMed Web of Science ®Google Scholar
• . Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7–14
   PubMedGoogle Scholar
• . Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70( suppl 5):18–22
   PubMed Web of Science ®Google Scholar
• . Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med. 2005;28(3):132–139
   PubMed Web of Science ®Google Scholar
• . Echols JC, Naidoo U, Salzman C. SAMe (S-adenosylmethionine). Harv Rev Psychiatry. 2000;8(2):84–90
   PubMed Web of Science ®Google Scholar
• . Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry. 2006;163(6):969–978
   PubMed Web of Science ®Google Scholar
• . Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056–1061
   PubMed Web of Science ®Google Scholar
• . Peet M, Horrobin DF. A dose-ranging study of the effects of ethyleicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59(10):913–919
   PubMed Web of Science ®Google Scholar
• . Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry. 2000;61( suppl 2):13–19
   PubMed Web of Science ®Google Scholar
• . Chengappa KN, Levine J, Gershon S,. Inositol as an add-on treatment for bipolar depression. Bipolar Disord. 2000;2(1):47–55
   PubMed Web of Science ®Google Scholar
• . Levine J, Barak Y, Gonzalves M,. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 1995;152(5):792–794
   PubMed Web of Science ®Google Scholar
• . Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry. 1999;45(3):270–273
   PubMed Web of Science ®Google Scholar
• . Nemets B, Mishory A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm. 1999;106(7–8):795–798
   PubMed Web of Science ®Google Scholar
• . Nierenberg AA, Mischoulon D, DeCecco L. St. John's wort: a critique of antidepressant efficacy and possible mechanisms of action. In: Mischoulon D, Rosenbaum JF, eds. Natural Medications for Psychiatric Disorders. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002:3–12
   Google Scholar
• . Linde K, Mulrow CD. St John's wort for depression. Cochrane Database Syst Rev. 2004;(4):CD000448
   Google Scholar
• . Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med. 2006;4:14
   PubMed Web of Science ®Google Scholar
• . Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiary. 2002;159(8):1361–1366
   PubMed Web of Science ®Google Scholar
• . Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807–1814
   PubMed Web of Science ®Google Scholar
• . Shelton RC, Keller MB, Gelenberg A,. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978–1986
   PubMed Web of Science ®Google Scholar
• . Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008;8(4):CD000448
   Google Scholar
• . Eschweiler GW, Vonthein R, Bode R,. Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): a short-term randomised controlled trial in pharmaco-resistant major depression. J Affect Disord. 2007;101(1–3):149–157
   PubMed Web of Science ®Google Scholar
• . Sackeim HA, Dillingham EM, Prudic J,. Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiatry. 2009;66(7):729–737
   PubMed Web of Science ®Google Scholar
• . Rasmussen KG, Mueller M, Rummans TA,. Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? Data from the Consortium for Research on Electroconvulsive Therapy (CORE). J Clin Psychiatry. 2009;70(2):232–237
   PubMed Web of Science ®Google Scholar
• . Cowey A. The Ferrier Lecture 2004 what can transcranial magnetic stimulation tell us about how the brain works? Philos Trans R Soc Lond B Biol Sci. 2005;360(1458):1185–1205
   PubMed Web of Science ®Google Scholar
• . Rogers MA, Kasai K, Koji M,. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res. 2004;50(1):1–11
   PubMed Web of Science ®Google Scholar
• . Fitzgerald PB, Hoy K, McQueen S,. Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. J Clin Psychopharmacol. 2008;28(1):52–58
   PubMed Web of Science ®Google Scholar
• . Gross M, Nakamura L, Pascual-Leone A, Fregni F. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. Acta Psychiatr Scand. 2007;116(3):165–173
   PubMed Web of Science ®Google Scholar
• . O'Reardon JP, Solvason HB, Janicak PG,. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208–1216
   PubMed Web of Science ®Google Scholar
• . George MS, Lisanby SH, Avery D,. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507–516
   PubMed Web of Science ®Google Scholar
• . Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry. 2008;53(9):621–631
   PubMed Web of Science ®Google Scholar
• . Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology. 2003;28(10):1852–1865
   PubMed Web of Science ®Google Scholar
• . Spellman T, McClintock SM, Terrace H, Luber B, Husain MM, Lisanby SH. Differential effects of high-dose magnetic seizure therapy and electroconvulsive shock on cognitive function. Biol Psychiatry. 2008;63(12):1163–1170
   PubMed Web of Science ®Google Scholar
• . Rush AJ, George MS, Sackeim HA,. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47(4):276–286
   PubMed Web of Science ®Google Scholar
• . Marangell LB, Rush AJ, George MS,. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002;51(4):280–287
   PubMed Web of Science ®Google Scholar
• . Nahas Z, Marangell LB, Husain MM,. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66(9):1097–1104
   PubMed Web of Science ®Google Scholar
• . Rush AJ, Marangell LB, Sackeim HA,. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58(5):347–354
   PubMed Web of Science ®Google Scholar
• . Rush AJ, Sackeim HA, Marangell LB,. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58(5):355–363
   PubMed Web of Science ®Google Scholar
• . George MS, Rush AJ, Marangell LB,. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58(5):364–373
   PubMed Web of Science ®Google Scholar
• . Kopell BH, Greenberg B, Rezai AR. Deep brain stimulation for psychiatric disorders. J Clin Neurophysiol. 2004;21(1):51–67
   PubMed Web of Science ®Google Scholar
• . Surguladze S, Keedwell P, Phillips M. Neural systems underlying affective disorders. Adv Psychiat Treat. 2003;9(6):446–455
   Google Scholar
• . Pressman JD. Last Resort: Psychosurgery and the Limits of Medicine. Cambridge, UK: Cambridge University Press; 1998
   Google Scholar
• . Valenstein ES. Great and Desperate Cures: The Rise and Decline of Psychosurgery and Other Radical Treatments for Mental Illness. New York, NY: Basic Books; 1986
   Google Scholar
• . Binder DK, Iskandar BJ. Modern neurosurgery for psychiatric disorders. Neurosurgery. 2000;47(1):9–23
   PubMed Web of Science ®Google Scholar
• . Eljamel MS. Ablative neurosurgery for mental disorders: is there still a role in the 21st century? A personal perspective. Neurosurg Focus. 2008;25(1):E4
   Web of Science ®Google Scholar
• . Steele JD, Christmas D, Eljamel MS, Matthews K. Anterior cingulotomy for major depression: clinical outcome and relationship to lesion characteristics. Biol Psychiatry. 2008;63(7):670–677
   PubMed Web of Science ®Google Scholar
• . Greenberg BD, Price LH, Rauch SL,. Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg Clin N Am. 2003;14(2):199–212
   PubMed Web of Science ®Google Scholar
• . Friedland DR, Gaggl W, Runge-Samuelson C, Ulmer JL, Kopell BH. Feasibility of auditory cortical stimulation for the treatment of tinnitus. Otol Neurotol. 2007;28(8):1005–1012
   PubMed Web of Science ®Google Scholar
• . Harvey RL, Nudo RJ. Cortical brain stimulation: a potential therapeutic agent for upper limb motor recovery following stroke. Top Stroke Rehabil. 2007;14(6):54–67
   PubMed Web of Science ®Google Scholar
• . Dougherty DD, Thase ME, Howland RH,. Feasibility study of an implantable cortical stimulation system for patients with major depressive disorder. Biol Psychiatry. 2008;63(7):294S–295S
   Web of Science ®Google Scholar
• . Howland RH, Thase ME, Evans K,. Feasibility study of an implantable cortical stimulation system for patients with major depressive disorder. New Research Abstract NR3–104. Presented at: 161st Annual American Psychiatric Association Meeting; Washington, DC; 2008
   Google Scholar
• . Kopell BH, Kondziolka D, Dougherty DD,. Feasibility study of the safety and effectiveness of an implantable cortical stimulation system for subjects with major depression [abstract 863]. Neurosurgery. 2007;61(1):215
   Web of Science ®Google Scholar
• . Alonso-Alonso M, Pascual-Leone A. The right brain hypothesis for obesity. JAMA. 2007;297(16):1819–1822
   PubMed Web of Science ®Google Scholar
• . Nahas Z, Anderson BS, Borckardt J,. Bilateral epidural prefrontal cortical stimulation for treatment-resistant depression. Biol Psychiatry. 2010;67(2):101–109
   PubMed Web of Science ®Google Scholar
• . Pereira EA, Green AL, Nandi D, Aziz TZ. Deep brain stimulation: indications and evidence. Expert Rev Med Devices. 2007;4(5):591–603
   PubMed Web of Science ®Google Scholar
• . Pilitsis JG, Metman LV, Toleikis JR, Hughes LE, Sani SB, Bakay RA. Factors involved in long-term efficacy of deep brain stimulation of the thalamus for essential tremor. J Neurosurg. 2008;109(4):640–646
   PubMed Web of Science ®Google Scholar
• . Moro E, Lang AE. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother. 2006;6(11):1695–1705
   PubMedGoogle Scholar
• . Abelson JL, Curtis GC, Sagher O,. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry. 2005;57(5):510–516
   PubMed Web of Science ®Google Scholar
• . Greenberg BD, Malone DA, Friehs GM,. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006;31(11):2384–2393
   PubMed Web of Science ®Google Scholar
• . Nuttin BJ, Gabriëls LA, Cosyns PR,. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery. 2003;52(6):1263–1274
   PubMed Web of Science ®Google Scholar
• . Hauptman JS, DeSalles AAF, Espinoza R, Sedrak M, Ishida W. Potential surgical targets for deep brain stimulation in treatment-resistant depression. Neurosurg Focus. 2008;25(1):E3
   Web of Science ®Google Scholar
• . Agid Y, Buzsáki G, Diamond DM,. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov. 2007;6(3):189–201
   PubMed Web of Science ®Google Scholar
• . Mayberg HS, Lozano AM, Voon V,. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651–660
   PubMed Web of Science ®Google Scholar
• . Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008;64(6):461–467
   PubMed Web of Science ®Google Scholar
• . Greenberg B, Friehs G, Carpenter L,. Deep brain stimulation: clinical findings in intractable depression and OCD [abstract]. Neuropsychopharmacol. 2004;29:S32
   PubMed Web of Science ®Google Scholar
• . Malone DA Jr, Dougherty DD, Rezai AR,. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009;65(4):267–275
   PubMed Web of Science ®Google Scholar
• . Bewernick BH, Hurlemann R, Matusch A,. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. 2010;67(2):110–116
   PubMed Web of Science ®Google Scholar
• . Miller L, Weissman M. Interpersonal psychotherapy delivered over the telephone to recurrent depressives. A pilot study. Depress Anxiety. 2002;16(3):114–117
   PubMed Web of Science ®Google Scholar
• . Ludman EJ, Simon GE, Tutty S, Von Korff M. A randomized trial of telephone psychotherapy and pharmacotherapy for depression: continuation and durability of effects. J Consult Clin Psychol. 2007;75(2):257–266
   PubMed Web of Science ®Google Scholar
• . Wisniewski SR, Fava M, Trivedi MH,. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry. 2007;164(5):753–760
   PubMed Web of Science ®Google Scholar
• . Committee on the Use of Complementary and Alternative Medicine by the American Public. Complementary and Alternative Medicine in the United States. Washington, DC: Committee on the Use of Complementary and Alternative Medicine by the American Public, Board on Health Promotion and Disease Prevention, Institute of Medicine of the National Academies, The National Academies Press; 2005
   Google Scholar
• . Gardner DM. Evidence-based decisions about herbal products for treating mental disorders. J Psychiatry Neurosci. 2002;27(5):324–333
   PubMed Web of Science ®Google Scholar
• . Ernst E. Serious psychiatric and neurological adverse effects of herbal medicines—a systematic review. Acta Psychiatr Scand. 2003;108(2):83–91
   PubMed Web of Science ®Google Scholar
• . McKenzie J, Keller HH. Who are the users of vitamin-mineral and herbal preparations among community-living older adults? Can J Aging. 2003;22:167–175
   Web of Science ®Google Scholar
• . Crowe S, Lyons B. Herbal medicine use by children presenting for ambulatory anesthesia and surgery. Paediatr Anaesth. 2004;14(11):916–919
   PubMed Web of Science ®Google Scholar
• . Nordeng H, Havnen GC. Impact of socio-demographic factors, knowledge and attitude on the use of herbal drugs in pregnancy. Acta Obstet Gynecol Scand. 2005;84(1):26–33
   PubMed Web of Science ®Google Scholar
• . Cott JM. Herb-drug interactions: focus on pharmacokinetics. CNS Spectr. 2001;6(10):827–832
   PubMedGoogle Scholar
• . Ernst E. Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf. 2004;13(11):767–771
   PubMed Web of Science ®Google Scholar
• . McCabe S. Complementary herbal and alternative drugs in clinical practice. Perspect Psychiatr Care. 2002;38(3):98–107
   PubMed Web of Science ®Google Scholar